Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to ...

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

Clarity Pharmaceuticals (ASX:CU6) has seen the U.S. FDA fast-track its prostate cancer imaging compound for use in PET scans on patients with recurring prostate cancer. The stock jumped 4% in the ...

These services include specialized options tailored to various cancer types. The PSMA PET CT scan is designed for prostate ...

While prostate cancer is becoming more prevalent among middle-aged and elderly men in China, clinical practice still faces considerable challenges due to the lack of unified guidelines and high-level ...

Prostate cancer is rapidly emerging as a significant health challenge in China, with the incidence rate steadily rising.

PSMA PET scans, for instance, enable precise detection of prostate cancer even in its earliest stages ... significantly ...

Telix Pharma’s prostate cancer PET1 imaging agent, Illuccix receives European marketing approval: Melbourne, Australia Saturday, January 18, 2025, 10:00 Hrs [IST] Telix Pharmace ...

In morning trade on Friday, the ASX 200 healthcare stock is up 4.5% to a record high of $27.00. Get the latest from The ...

Telix’s lead imaging product, gallium-68 ( 68 Ga) gozetotide injection (also known as 68 Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug ...

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive ...